What is the recommended intravenous silibinin dosing regimen and monitoring for acute liver injury (e.g., mushroom poisoning, drug‑induced hepatotoxicity)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Intravenous Silibinin for Acute Liver Injury

For acute liver failure from mushroom poisoning or drug-induced hepatotoxicity, administer intravenous silibinin at 30-40 mg/kg/day divided over 24 hours for 3-4 days, starting as soon as possible after exposure. 1

Dosing Regimen

The AASLD guideline establishes the standard dosing protocol:

  • Dose: 30-40 mg/kg/day (either intravenously or orally)
  • Duration: 3-4 days on average
  • Route: IV preferred when available; oral formulations may be used if IV unavailable 1

Critical timing consideration: Silibinin remains effective even when initiated up to 48 hours after mushroom ingestion, though earlier administration correlates with better outcomes 2. The delay between ingestion and treatment initiation directly correlates with severity of liver damage.

Primary Indication

Mushroom poisoning (particularly Amanita phalloides) represents the strongest indication. The AASLD formally recommends considering silibinin administration in all ALF patients with known or suspected mushroom poisoning 1. Silibinin has demonstrated superior outcomes compared to penicillin G alone, with mortality rates under 10% in treated patients versus over 20% with penicillin or combination therapy 3.

Mechanism and Rationale

Silibinin blocks hepatic transport proteins, preventing cellular amatoxin re-uptake and interrupting enterohepatic circulation of the toxin 3. This antioxidant and anti-inflammatory flavonolignan also stimulates ribosomal RNA synthesis and protects cell membranes from radical-induced damage 4.

Availability and Practical Considerations

Major caveat: Silibinin is not FDA-approved as a licensed drug in the United States, though widely available in Europe and South America 1. In the U.S., only oral milk thistle extracts (containing 70-80% silymarin) are commercially available as unregulated supplements with variable concentrations 1. Supply challenges have occurred during poisoning clusters 5.

For drug-induced hepatotoxicity beyond acetaminophen, the evidence is less robust than for mushroom poisoning, but the same dosing regimen applies given the lack of alternative treatments and minimal adverse effects 6.

Monitoring Parameters

Monitor these parameters during treatment:

  • Hepatic function: AST, ALT, bilirubin, INR/PT (mushroom poisoning typically shows AST/ALT >4000 U/L with markedly elevated INR) 7
  • Renal function: Creatinine, as acute kidney injury commonly accompanies severe hepatotoxicity 8
  • MELD-Na score: Prognostic indicator (scores >30 indicate severe injury requiring transplant consideration) 7
  • Clinical status: Mental status changes, coagulopathy progression

Concurrent Management

Always combine with:

  • Aggressive IV fluid resuscitation 1
  • Early transplant center contact and listing evaluation 1
  • Gastric lavage and activated charcoal if presenting within hours of ingestion 1
  • Penicillin G (300,000-1 million units/kg/day IV) may be added, though silibinin shows superior efficacy 1

Discontinue all non-essential medications in drug-induced hepatotoxicity cases 1.

Important Caveats

  • No controlled trials exist proving silibinin efficacy due to ethical constraints, but extensive case series and uncontrolled trials support its use 3
  • Adverse effects are rare (occasional nausea, mild laxative effect, urticaria) 4
  • Transplant remains the definitive lifesaving option for severe cases; silibinin does not replace transplant evaluation 1
  • Recent data suggest oral silymarin may reduce acute kidney injury but has not demonstrated mortality reduction in all studies 8

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.